Dermira Inc (DERM) Insider Eugene A. Bauer Sells 3,000 Shares
Dermira Inc (NASDAQ:DERM) insider Eugene A. Bauer sold 3,000 shares of Dermira stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $27.34, for a total transaction of $82,020.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Dermira Inc (NASDAQ DERM) traded up $1.20 on Wednesday, reaching $27.87. 424,704 shares of the company’s stock traded hands, compared to its average volume of 428,871. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira Inc has a 12 month low of $21.35 and a 12 month high of $38.75.
DERM has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $45.00 target price on shares of Dermira in a report on Monday, November 6th. Zacks Investment Research downgraded shares of Dermira from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Guggenheim initiated coverage on shares of Dermira in a report on Tuesday, December 5th. They issued a “buy” rating for the company. Leerink Swann restated an “outperform” rating and issued a $41.00 target price (down from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Finally, Mizuho restated a “buy” rating and issued a $43.00 target price (up from $40.00) on shares of Dermira in a report on Thursday, September 7th. Four research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Dermira currently has a consensus rating of “Hold” and a consensus target price of $41.00.
COPYRIGHT VIOLATION NOTICE: “Dermira Inc (DERM) Insider Eugene A. Bauer Sells 3,000 Shares” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/12/20/dermira-inc-derm-insider-eugene-a-bauer-sells-3000-shares.html.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.